Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Cole, Michelle J ^a   Spiteri, Gianfranco ^b   Jacobsson, Susanne ^c   Woodford, Neil ^a   Tripodo, Francesco ^a   Amato Gauci, Andrew J ^b   Unemo, Magnus ^c   Indra, Alexander ^d   Maes, Virginie ^d   Crucitti, Tania ^d   Hunjak, Blaženka ^d   Blažic, Tatjana Nemeth ^d   Soteriou, Soteroulla ^d   Maikanti Charalambous, Panayiota ^d   Pieridou, Despo ^d   Cowan, Susan ^d   Hoffmann, Steen ^d   Epstein, Jevgenia ^d   Viktorova, Jelena ^d   Ndeikoundam, Ndeindo ^d   Goubard, Agathe ^d   Kohl, Peter ^d   Buder, Susanne ^d   Bremer, Viviane ^d   Jansen, Klaus ^d   Tzelepi, Eva ^d   Konte, Vasileia ^d   Balla, Eszter ^d   Dudás, Mária ^d   Sigmundsdóttir, Gudrún ^d   Hauksdóttir, Gudrún Svanborg ^d   Igoe, Derval ^d   Crowley, Brendan ^d   Suligoi, Barbara ^d   Stefanelli, Paola ^d   Pakarna, Gatis ^d   Mavcutko, Violeta ^d   Barbara, Christopher ^d   Vella, Francesca ^d   Melillo, Jackie Maistre ^d   Dam, Alje Van ^d   Benthem, Birgit Van ^d   Linde, Ineke ^d   Kløvstad, Hilde ^d   Bergheim, Thea ^d   Majewski, Slawomir ^d   Mlynarczyk Bonikowska, Beata ^d   Azevedo, Jacinta ^d   Borrego, Maria José ^d   Pavlik, Peter ^d   Truska, Peter ^d   Klavs, Irena ^d   Jeverica, Samo ^d   Vazquez, Julio ^d   Díaz, Asunción ^d   Velicko, Inga ^d   Hughes, Gwenda ^d   Templeton, Kate ^d   Irvine, Neil ^d   more..

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

^d NONE   (United Kingdom)

Author keywords

Antimicrobial resistance; Ceftriaxone; Europe; European Economic Area (EEA); European Gonococcal Antimicrobial Surveillance Programme (Euro GASP); European Union (EU); Gonorrhoea; Surveillance; Treatment

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGAR DILUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; CHLAMYDIASIS; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; EUROPE; FEMALE; GONORRHEA; HETEROSEXUAL MALE; HUMAN; INFANT; MALE; MEN WHO HAVE SEX WITH MEN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; CEPHALOSPORIN RESISTANCE; DRUG EFFECTS; HETEROSEXUALITY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PROCEDURES; SENTINEL SURVEILLANCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN RESISTANCE; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; EUROPE; FEMALE; GONORRHEA; HETEROSEXUALITY; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEISSERIA GONORRHOEAE; SENTINEL SURVEILLANCE; YOUNG ADULT;

EID: 85029210382     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2707-z     Document Type: Article

References (34)

1. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27:587-613.
2. World Health Organisation. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. 2012. http://whqlibdoc.who.int/publications/2012/9789241503501_eng.pdf. Accessed 02 Aug 2017.
3. European Centre for Disease Prevention and Control. Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe. 2012. http://www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf. Accessed 02 Aug 2017.
4. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24:85-92.
5. European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe 2014. 2016. http://ecdc.europa.eu/en/publications/Publications/gonococcal-antimicrobial-susceptibility-surveillance-Europe-2014.pdf. Accessed 02 Aug 2017.
6. Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, Unemo M. Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. N Engl J Med. 2016;374:2504-6.
7. European Centre for Disease Prevention and Control. Euro-GASP external quality assessment scheme, 2015 for Neisseria gonorrhoeae antimicrobial susceptibility testing. 2016. http://antibiotic.ecdc.europa.eu/en/publications/Publications/EQA-Eur-GASP-2015-Gono.pdf. Accessed 02 Aug 2017.
8. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. 2017. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf. Accessed 02 Aug 2017.
9. Kirkcaldy RD, Harvey A, Papp JR, Del Rio C, Soge OO, Holmes KK, Hook EW 3rd, Kubin G, Riedel S, Zenilman J, et al. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. MMWR Surveill Summ. 2016;65:1-19.
10. Martin I, Sawatzky P, Liu G, Allen V, Lefebvre B, Hoang L, Drews S, Horsman G, Wylie J, Haldane D, et al. Decline in Decreased Cephalosporin Susceptibility and Increase in Azithromycin Resistance in Neisseria gonorrhoeae, Canada. Emerg Infect Dis. 2016;22:65-7.
11. Lahra MM. Australian Gonococcal Surveillance Programme annual report, 2014. Commun Dis Intell Q Rep. 2015;39:E347-54.
12. Tanaka M, Furuya R, Irie S, Kanayama A, Kobayashi I. High Prevalence of Azithromycin-Resistant Neisseria gonorrhoeae Isolates With a Multidrug Resistance Phenotype in Fukuoka, Japan. Sex Transm Dis. 2015;42:337-41.
13. Chen SC, Yin YP, Dai XQ, Unemo M, Chen XS. First nationwide study regarding ceftriaxone resistance and molecular epidemiology of Neisseria gonorrhoeae in China. J Antimicrob Chemother. 2015;
14. Kirkcaldy RD, Soge O, Papp JR, Hook EW III, Del RC, Kubin G, Weinstock HS. Analysis of Neisseria gonorrhoeae Azithromycin Susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013. Antimicrob Agents Chemother. 2015;59:998-1003.
15. Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH Jr, Schrag SJ. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60:1308-16.
16. Public Health England. Surveillance of antimicrobial resistance in Neisseria gonorrhoeae. 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/567602/GRASP_Report_2016.pdf. Accessed 02 Aug 2017.
17. Ni C, Xue J, Zhang C, Zhou H, van der Veen S. High prevalence of Neisseria gonorrhoeae with high-level resistance to azithromycin in Hangzhou, China. J Antimicrob Chemother. 2016;71:2355-7.
18. Chisholm SA, Wilson J, Alexander S, Tripodo F, Al-Shahib A, Schaefer U, Lythgow K, Fifer H. An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England. Sex Transm Infect. 2016;92:365-7.
19. Papp JR, Abrams AJ, Nash E, Katz AR, Kirkcaldy RD, O'Connor NP, O'Brien PS, Harauchi DH, Maningas EV, Soge OO, et al. Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in Neisseria gonorrhoeae, Hawaii, USA. Emerg Infect Dis. 2017;23:830-2.
20. Jacobsson S, Golparian D, Cole M, Spiteri G, Martin I, Bergheim T, Borrego MJ, Crowley B, Crucitti T, Van Dam AP, et al. WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2 mg/L) Neisseria gonorrhoeae isolates in Europe from 2009 to 2014. J Antimicrob Chemother. 2016;71:3109-16.
21. Liang JY, Cao WL, Li XD, Bi C, Yang RD, Liang YH, Li P, Ye XD, Chen XX, Zhang XB. Azithromycin-resistant Neisseria gonorrhoeae isolates in Guangzhou, China (2009-2013): coevolution with decreased susceptibilities to ceftriaxone and genetic characteristics. BMC Infect Dis. 2016;16:152.
22. Allen VG, Seah C, Martin I, Melano RG. Azithromycin resistance is co-evolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae, Ontario, Canada. Antimicrob Agents Chemother. 2014;58:2528-34.
23. Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, van de Laar MJ. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill. 2013;18 pii: 20358
24. Demczuk W, Lynch T, Martin I, Van Domselaar G, Graham M, Bharat A, Allen V, Hoang L, Lefebvre B, Tyrrell G, et al. Whole-genome phylogenomic heterogeneity of Neisseria gonorrhoeae isolates with decreased cephalosporin susceptibility collected in Canada between 1989 and 2013. J Clin Microbiol. 2015;53:191-200.
25. Bignell C, Fitzgerald M. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS. 2011;22:541-7.
26. World Health Organisation. WHO Guidelines for the treatment of Neisseria gonorrhoeae. 2016. http://apps.who.int/iris/bitstream/10665/246114/1/9789241549691-eng.pdf?ua=1. Accessed 02 Aug 2017.
27. Plourde PJ, Tyndall M, Agoki E, Ombette J, Slaney LA, D'Costa LJ, Ndinya-Achola JO, Plummer FA. Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection. J Infect Dis. 1992;166:919-22.
28. Haizlip J, Isbey SF, Hamilton HA, Jerse AE, Leone PA, Davis RH, Cohen MS. Time required for elimination of Neisseria gonorrhoeae from the urogenital tract in men with symptomatic urethritis: comparison of oral and intramuscular single-dose therapy. Sex Transm Dis. 1995;22:145-8.
29. Ramus RM, Sheffield JS, Mayfield JA, Wendel GD Jr. A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. Am J Obstet Gynecol. 2001;185:629-32.
30. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65:2141-8.
31. Woodford N, Ison CA. The effect of media on antimicrobial susceptibility testing of Neisseria gonorrhoeae. J Antimicrob Chemother. 1988;22:463-71.
32. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
33. Australasian Sexual Health Alliance. Australian STI Management Guidelines for Use in Primary Care 2016. www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea#management Accessed 02 Aug 2017.
34. Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections. 2013. www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/assets/pdf/section-5-6-eng.pdf. Accessed 02 Aug 2017.